Echo IQ (ASX:EIQ) Expands Mayo Clinic Partnership to Tackle Hidden Heart Risks in Cancer Care

Key Highlights:

• Echo IQ (ASX:EIQ) has launched a new research collaboration with Mayo Clinic Arizona focused on cardio-oncology.
• Study will assess whether Echo IQ’s AI platform can predict heart failure risk in cancer patients undergoing treatment.
• Research builds on Echo IQ’s existing relationship with Mayo Clinic, which already acts as a commercial reseller across more than 80 partner hospitals.
• Results and a co-authored peer-reviewed publication are targeted for the first half of 2027.

Artificial intelligence is increasingly finding a place in modern medicine, and Echo IQ (ASX:EIQ) is aiming to position itself at the intersection of cardiology and oncology through a new research collaboration with one of the world’s most respected healthcare institutions.

The Australian health technology company announced it has partnered with Mayo Clinic Arizona to evaluate its AI-powered cardiac risk assessment platform in cancer patients undergoing treatment. The study will investigate whether Echo IQ’s technology can identify early signs of heart damage before symptoms emerge, potentially helping doctors intervene sooner.

The collaboration will be led by Dr Chadi Ayoub at Mayo Clinic Arizona under a study titled Evaluation of Cardiotoxicity in Patients Receiving Cancer Therapy and Risk Stratification.

Cancer treatments have become increasingly effective over the past decade, helping patients live longer than ever before. However, many therapies can place significant stress on the heart, creating a growing challenge for healthcare systems worldwide. This emerging field, known as cardio-oncology, focuses on managing cardiovascular complications linked to cancer treatment.

Rather than relying on additional testing, Echo IQ’s platform will analyse routinely collected echocardiogram data within a secure environment to generate predictive heart failure risk scores.

The announcement expands an already established relationship between Echo IQ and Mayo Clinic. The healthcare giant currently acts as a master commercial reseller for Echo IQ’s software suite across a network of more than 80 affiliated hospitals, giving the company a significant foothold within the US healthcare market.

The market reaction was relatively measured. Shares in Echo IQ (ASX:EIQ) were trading at $1.155 on Friday, down by 2.53%. Despite the slight decline, the stock has delivered a remarkable 413.33% return over the past 12 months and remains one of the stronger performers in the ASX healthcare technology space. 

Source: MarketIndex 

For Echo IQ, the significance of the agreement extends beyond a single study.

The company has built its reputation around AI-driven cardiac diagnostics, particularly in detecting heart failure and aortic stenosis. While its existing commercial focus has centred on traditional cardiology settings, the Mayo collaboration opens the door to a much larger patient population.

Globally, more than 20 million new cancer cases are diagnosed each year, according to international health data. As survival rates continue to improve, hospitals are increasingly focused on monitoring long-term complications that can emerge years after treatment ends.

Chief Executive Officer Dustin Haines said the project addresses a growing clinical need.

“This collaboration with Mayo Clinic represents an important opportunity to evaluate the Company’s cardiac AI platform in a high-need clinical population, where earlier identification of cardiovascular risk may inform clinical decision making.”

“As cancer survival rates continue to improve, healthcare systems are increasingly focused on managing the long-term cardiac consequences of cancer therapy. We are excited by the prospect of assessing whether routinely acquired echocardiographic data can be used to generate meaningful predictive insights for clinicians.”

The study is expected to conclude in the first half of 2027, with both organisations targeting publication of the findings in a peer-reviewed medical journal.

The announcement also follows several recent milestones for the company. In May, Echo IQ received a $762,000 R&D Tax Incentive refund, strengthening its cash position. The company has also continued progressing regulatory pathways for its heart failure platform in the United States, an area viewed as a major future growth driver.

While commercialisation of any cancer-specific application remains some distance away, the collaboration offers another layer of validation for Echo IQ’s technology and reinforces its ties with one of the world’s leading medical institutions.

For a company seeking to expand beyond traditional cardiology, the Mayo Clinic relationship could prove to be as strategically important as the technology itself.